 Ajay Major
Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2026 | 193 | 4.440 |
Why?
| | Hematologic Neoplasms | 3 | 2025 | 168 | 2.170 |
Why?
| | Antibodies, Bispecific | 4 | 2026 | 68 | 2.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 16 | 2026 | 1963 | 1.860 |
Why?
| | Hodgkin Disease | 6 | 2026 | 171 | 1.840 |
Why?
| | Multiple Myeloma | 9 | 2024 | 309 | 1.780 |
Why?
| | Lymphoma, Follicular | 2 | 2026 | 56 | 1.510 |
Why?
| | Patient Reported Outcome Measures | 3 | 2026 | 497 | 1.450 |
Why?
| | Neoplasms, Second Primary | 2 | 2026 | 102 | 1.410 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 124 | 1.400 |
Why?
| | Lymphoma | 4 | 2026 | 237 | 1.300 |
Why?
| | Medical Oncology | 5 | 2024 | 339 | 1.300 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 699 | 1.300 |
Why?
| | Neoplasms | 6 | 2026 | 2906 | 1.270 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2026 | 198 | 1.200 |
Why?
| | Cancer Survivors | 2 | 2026 | 337 | 1.050 |
Why?
| | Immunotherapy, Adoptive | 4 | 2026 | 342 | 0.990 |
Why?
| | Vascular Access Devices | 1 | 2025 | 30 | 0.900 |
Why?
| | Lymphoma, B-Cell | 3 | 2026 | 140 | 0.870 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2214 | 0.870 |
Why?
| | Survivors | 2 | 2026 | 523 | 0.830 |
Why?
| | Catheterization, Central Venous | 1 | 2025 | 123 | 0.800 |
Why?
| | Immunotherapy | 2 | 2026 | 666 | 0.790 |
Why?
| | Quality of Life | 6 | 2026 | 3204 | 0.750 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 1149 | 0.750 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 261 | 0.740 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 57 | 0.720 |
Why?
| | Humans | 65 | 2026 | 145475 | 0.720 |
Why?
| | Plasma Exchange | 1 | 2021 | 18 | 0.700 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 18 | 0.690 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 134 | 0.670 |
Why?
| | Vaccination | 2 | 2021 | 1426 | 0.670 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 16 | 0.670 |
Why?
| | Dexamethasone | 7 | 2024 | 365 | 0.670 |
Why?
| | Cyclophosphamide | 4 | 2024 | 270 | 0.660 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 29 | 0.650 |
Why?
| | Hospice Care | 1 | 2024 | 227 | 0.640 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1061 | 0.620 |
Why?
| | Internship and Residency | 2 | 2021 | 1267 | 0.610 |
Why?
| | Terminal Care | 1 | 2024 | 283 | 0.610 |
Why?
| | Drug Costs | 1 | 2020 | 117 | 0.580 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 117 | 0.560 |
Why?
| | Internal Medicine | 1 | 2021 | 279 | 0.540 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 31 | 0.530 |
Why?
| | Colorectal Neoplasms | 1 | 2026 | 866 | 0.530 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1329 | 0.520 |
Why?
| | Treatment Outcome | 15 | 2026 | 11772 | 0.520 |
Why?
| | Aged | 24 | 2026 | 26153 | 0.510 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 22 | 0.510 |
Why?
| | Etoposide | 3 | 2024 | 168 | 0.500 |
Why?
| | Oncologists | 1 | 2017 | 47 | 0.500 |
Why?
| | Middle Aged | 24 | 2026 | 36215 | 0.490 |
Why?
| | Vincristine | 3 | 2024 | 142 | 0.490 |
Why?
| | Neoplasm, Residual | 4 | 2024 | 143 | 0.490 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 177 | 0.490 |
Why?
| | Oligopeptides | 5 | 2024 | 267 | 0.490 |
Why?
| | Immunocompromised Host | 1 | 2018 | 202 | 0.480 |
Why?
| | Mental Health Services | 1 | 2021 | 473 | 0.460 |
Why?
| | Medicare | 2 | 2023 | 903 | 0.450 |
Why?
| | Aged, 80 and over | 13 | 2026 | 8333 | 0.440 |
Why?
| | Empathy | 1 | 2017 | 181 | 0.440 |
Why?
| | Doxorubicin | 3 | 2024 | 401 | 0.430 |
Why?
| | Health Personnel | 1 | 2021 | 754 | 0.420 |
Why?
| | Mental Health | 1 | 2021 | 793 | 0.410 |
Why?
| | Adult | 21 | 2026 | 40777 | 0.410 |
Why?
| | Prognosis | 8 | 2026 | 4316 | 0.410 |
Why?
| | Hematology | 3 | 2024 | 21 | 0.400 |
Why?
| | Students, Medical | 2 | 2021 | 378 | 0.400 |
Why?
| | Rituximab | 3 | 2024 | 210 | 0.400 |
Why?
| | Male | 27 | 2026 | 72843 | 0.400 |
Why?
| | Bullying | 1 | 2014 | 44 | 0.390 |
Why?
| | Curriculum | 1 | 2020 | 1070 | 0.390 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 300 | 0.380 |
Why?
| | Young Adult | 11 | 2026 | 14219 | 0.370 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1101 | 0.370 |
Why?
| | Physicians | 1 | 2021 | 955 | 0.360 |
Why?
| | Prednisone | 2 | 2024 | 224 | 0.360 |
Why?
| | SEER Program | 2 | 2026 | 229 | 0.360 |
Why?
| | Mental Disorders | 1 | 2021 | 1163 | 0.350 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 641 | 0.350 |
Why?
| | Healthcare Disparities | 1 | 2018 | 735 | 0.350 |
Why?
| | Delivery of Health Care | 1 | 2018 | 946 | 0.350 |
Why?
| | Pediatrics | 1 | 2020 | 1121 | 0.340 |
Why?
| | Female | 25 | 2026 | 78845 | 0.340 |
Why?
| | Faculty, Medical | 1 | 2014 | 303 | 0.320 |
Why?
| | Education, Medical | 1 | 2014 | 275 | 0.320 |
Why?
| | Skin Neoplasms | 1 | 2017 | 849 | 0.300 |
Why?
| | Neoplasm Staging | 4 | 2026 | 1471 | 0.300 |
Why?
| | Public Health Surveillance | 2 | 2020 | 83 | 0.290 |
Why?
| | Information Dissemination | 2 | 2022 | 224 | 0.280 |
Why?
| | Antibodies, Monoclonal | 4 | 2026 | 1505 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2026 | 992 | 0.260 |
Why?
| | Retrospective Studies | 10 | 2026 | 17291 | 0.250 |
Why?
| | Fatal Outcome | 2 | 2017 | 305 | 0.240 |
Why?
| | Minimal Clinically Important Difference | 1 | 2026 | 31 | 0.240 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6066 | 0.240 |
Why?
| | Michigan | 1 | 2025 | 134 | 0.230 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 36 | 0.220 |
Why?
| | Databases, Factual | 2 | 2022 | 1490 | 0.220 |
Why?
| | Drug Administration Schedule | 1 | 2026 | 782 | 0.210 |
Why?
| | Disease Management | 2 | 2018 | 653 | 0.210 |
Why?
| | Immunoconjugates | 1 | 2026 | 138 | 0.210 |
Why?
| | Methotrexate | 2 | 2023 | 233 | 0.200 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 20 | 0.200 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 99 | 0.200 |
Why?
| | Patient Preference | 1 | 2026 | 223 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2664 | 0.200 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 78 | 0.190 |
Why?
| | Azacitidine | 1 | 2024 | 157 | 0.190 |
Why?
| | Geriatrics | 1 | 2024 | 95 | 0.190 |
Why?
| | Hospices | 1 | 2024 | 92 | 0.190 |
Why?
| | Melphalan | 1 | 2022 | 43 | 0.180 |
Why?
| | Bortezomib | 1 | 2022 | 54 | 0.180 |
Why?
| | Time-to-Treatment | 1 | 2024 | 251 | 0.180 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 562 | 0.180 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 34 | 0.180 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 280 | 0.180 |
Why?
| | Watchful Waiting | 1 | 2022 | 90 | 0.180 |
Why?
| | Amyloidosis | 1 | 2022 | 44 | 0.170 |
Why?
| | Africa | 1 | 2022 | 119 | 0.170 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 101 | 0.170 |
Why?
| | Platelet Count | 1 | 2021 | 94 | 0.170 |
Why?
| | Incidence | 2 | 2026 | 2923 | 0.170 |
Why?
| | Adolescent | 6 | 2026 | 22530 | 0.170 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 106 | 0.170 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 20 | 0.170 |
Why?
| | Child | 5 | 2026 | 22707 | 0.160 |
Why?
| | Sirolimus | 1 | 2022 | 280 | 0.160 |
Why?
| | Health Occupations | 1 | 2020 | 36 | 0.160 |
Why?
| | United States | 5 | 2026 | 16098 | 0.160 |
Why?
| | Home Care Services | 1 | 2024 | 284 | 0.160 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 265 | 0.160 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 382 | 0.160 |
Why?
| | Sulfonamides | 1 | 2024 | 583 | 0.160 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 354 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2022 | 204 | 0.150 |
Why?
| | Frailty | 1 | 2023 | 205 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 198 | 0.150 |
Why?
| | Survivorship | 1 | 2020 | 57 | 0.150 |
Why?
| | Botulism | 1 | 2019 | 8 | 0.150 |
Why?
| | Medical Informatics | 1 | 2020 | 99 | 0.140 |
Why?
| | Personal Satisfaction | 1 | 2021 | 219 | 0.140 |
Why?
| | Program Development | 1 | 2021 | 368 | 0.140 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 454 | 0.140 |
Why?
| | Heroin Dependence | 1 | 2019 | 33 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2019 | 310 | 0.140 |
Why?
| | Pandemics | 3 | 2022 | 1707 | 0.140 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 207 | 0.140 |
Why?
| | Risk Factors | 4 | 2024 | 10885 | 0.130 |
Why?
| | Social Media | 1 | 2020 | 166 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 838 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 402 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 127 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 686 | 0.130 |
Why?
| | Prednisolone | 1 | 2017 | 67 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 136 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 53 | 0.120 |
Why?
| | Vaccines | 1 | 2022 | 388 | 0.120 |
Why?
| | Program Evaluation | 1 | 2021 | 943 | 0.120 |
Why?
| | Artificial Intelligence | 1 | 2021 | 381 | 0.120 |
Why?
| | Research | 1 | 2020 | 430 | 0.120 |
Why?
| | Narration | 1 | 2017 | 79 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 969 | 0.120 |
Why?
| | Machine Learning | 1 | 2021 | 587 | 0.110 |
Why?
| | Recurrence | 3 | 2026 | 1138 | 0.110 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 716 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 231 | 0.110 |
Why?
| | Pilot Projects | 1 | 2021 | 1891 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1327 | 0.110 |
Why?
| | Time Factors | 1 | 2026 | 7123 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1266 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 488 | 0.110 |
Why?
| | Child, Preschool | 2 | 2026 | 11853 | 0.100 |
Why?
| | Thalidomide | 2 | 2024 | 43 | 0.100 |
Why?
| | Anxiety | 1 | 2021 | 1118 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 4075 | 0.090 |
Why?
| | Cytokines | 1 | 2021 | 2067 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 1193 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2021 | 1146 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.090 |
Why?
| | Age Factors | 1 | 2020 | 3342 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1243 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 2046 | 0.090 |
Why?
| | Infant | 1 | 2026 | 10077 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1546 | 0.080 |
Why?
| | Prevalence | 1 | 2018 | 2865 | 0.080 |
Why?
| | Registries | 1 | 2020 | 2406 | 0.080 |
Why?
| | Colorado | 1 | 2021 | 4554 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2017 | 1196 | 0.070 |
Why?
| | Antigens, CD20 | 1 | 2025 | 34 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 24 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 42 | 0.050 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 11 | 0.050 |
Why?
| | Lymphoma, T-Cell | 1 | 2024 | 29 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2024 | 80 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 66 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2023 | 39 | 0.050 |
Why?
| | Hydrazines | 1 | 2023 | 37 | 0.050 |
Why?
| | Imides | 1 | 2022 | 5 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 41 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 223 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 136 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 172 | 0.040 |
Why?
| | Biotin | 1 | 2022 | 32 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5905 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2025 | 554 | 0.040 |
Why?
| | Injections, Spinal | 1 | 2022 | 119 | 0.040 |
Why?
| | Education, Premedical | 1 | 2021 | 5 | 0.040 |
Why?
| | Blogging | 1 | 2021 | 7 | 0.040 |
Why?
| | Triazoles | 1 | 2023 | 187 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1041 | 0.040 |
Why?
| | Geriatric Assessment | 1 | 2023 | 239 | 0.040 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 102 | 0.040 |
Why?
| | Professionalism | 1 | 2021 | 26 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 480 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 282 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 247 | 0.040 |
Why?
| | Plasma | 1 | 2022 | 223 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 376 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 420 | 0.040 |
Why?
| | Writing | 1 | 2021 | 101 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 899 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 444 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 881 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 13 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 503 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 53 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 60 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 409 | 0.030 |
Why?
| | Muscle Weakness | 1 | 2019 | 92 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2019 | 178 | 0.030 |
Why?
| | Biomedical Research | 1 | 2024 | 717 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 153 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 154 | 0.030 |
Why?
| | Dyspnea | 1 | 2019 | 250 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 343 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3747 | 0.020 |
Why?
| | Cohort Studies | 1 | 2023 | 6013 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|